ZA987847B - Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof - Google Patents

Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof

Info

Publication number
ZA987847B
ZA987847B ZA987847A ZA987847A ZA987847B ZA 987847 B ZA987847 B ZA 987847B ZA 987847 A ZA987847 A ZA 987847A ZA 987847 A ZA987847 A ZA 987847A ZA 987847 B ZA987847 B ZA 987847B
Authority
ZA
South Africa
Prior art keywords
uridine
diphosphate
analogs
lung diseases
treating lung
Prior art date
Application number
ZA987847A
Other languages
English (en)
Inventor
Richard C Boucher Jr
Sammy Ray Shaver
William Pendergast
Benjamin Yerxa
Janet L Rideout
Robert Dougherty
Dallas Croom
Original Assignee
Univ North Carolina
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Inspire Pharmaceuticals Inc filed Critical Univ North Carolina
Publication of ZA987847B publication Critical patent/ZA987847B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA987847A 1997-08-29 1998-08-28 Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof ZA987847B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5706497P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
ZA987847B true ZA987847B (en) 1999-06-28

Family

ID=22008285

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA987847A ZA987847B (en) 1997-08-29 1998-08-28 Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof

Country Status (14)

Country Link
US (3) US6143279A (xx)
EP (1) EP1011688B1 (xx)
JP (1) JP2001513568A (xx)
KR (1) KR20010023359A (xx)
CN (1) CN1268056A (xx)
AR (1) AR013454A1 (xx)
AT (1) ATE288273T1 (xx)
AU (1) AU9124998A (xx)
BR (1) BR9811612A (xx)
CA (1) CA2300146A1 (xx)
DE (1) DE69828892D1 (xx)
ID (1) ID29198A (xx)
WO (1) WO1999009998A1 (xx)
ZA (1) ZA987847B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
PT1012154E (pt) 1997-07-25 2004-08-31 Inspire Pharmaceuticals Inc Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes
CA2300146A1 (en) * 1997-08-29 1999-03-04 Richard C. Boucher, Jr. Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
WO2000039145A1 (en) * 1998-12-23 2000-07-06 The University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
BR0008498A (pt) * 1999-02-26 2002-02-05 Inspire Pharmaceuticals Inc Método de promoção de hidratação de mucosas com certos difosfatos de uridina, adenina e citidina e seus análogos
JP4969002B2 (ja) * 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
EP1282707A2 (en) * 2000-05-11 2003-02-12 Bayer Aktiengesellschaft Regulation of human p2y-like g protein-coupled receptor
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
WO2003000056A1 (en) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
WO2003024980A1 (fr) * 2001-09-14 2003-03-27 Universite De Liege Preparation de composes organiques triphosphoryles eventuellement marques au phosphore 32 ou au phosphore 33
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
CN1612739A (zh) 2001-11-06 2005-05-04 印斯拜尔药品股份有限公司 治疗或预防炎性疾病的方法
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7285658B2 (en) * 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
EP1560540A4 (en) * 2002-10-18 2008-03-19 Molichem Medicines Inc METHOD FOR TREATING DRY EYES WITH LANTIBIOTICS
CA2520028A1 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
EP1750740A4 (en) * 2004-05-06 2009-06-10 Molichem Medicines Inc TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc TREATMENT OF EYE DISEASES AND EYE TREATMENTS WITH LANTIBIOTIC COMPOSITIONS
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
US8618074B2 (en) 2007-03-15 2013-12-31 Board Of Regents Of The University Of Texas System GPCR enhanced neuroprotection to treat brain injury
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2556832B1 (en) * 2011-08-12 2017-07-19 Universitätsklinikum Freiburg Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease
IN2014CN03043A (xx) 2011-09-30 2015-07-03 Univ Tufts
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
WO2014052896A1 (en) 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
EP3428153A1 (en) 2012-12-17 2019-01-16 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
WO2014099676A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
DK2968385T3 (en) * 2013-03-13 2018-09-03 Univ Tufts URIDINNUCLEOSIDE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR USING THEREOF
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
KR20210077946A (ko) * 2019-12-18 2021-06-28 주식회사 종근당 우리딘 5’-디인산(udp), 이의 염 또는 이의 수화물의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639386A (xx) * 1962-10-30
DE2122529A1 (de) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
JPS5415073B2 (xx) * 1972-09-14 1979-06-12
US4058601A (en) * 1974-07-11 1977-11-15 Chugai Seiyaku Kabushiki Kaisha Method for treating alcoholism
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
AU738907C (en) * 1997-02-06 2002-05-16 Merck Sharp & Dohme Corp. Dinucleotides and their use
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
CA2300146A1 (en) * 1997-08-29 1999-03-04 Richard C. Boucher, Jr. Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases

Also Published As

Publication number Publication date
EP1011688B1 (en) 2005-02-02
ATE288273T1 (de) 2005-02-15
JP2001513568A (ja) 2001-09-04
CN1268056A (zh) 2000-09-27
BR9811612A (pt) 2000-08-08
AR013454A1 (es) 2000-12-27
DE69828892D1 (de) 2005-03-10
US6451288B1 (en) 2002-09-17
CA2300146A1 (en) 1999-03-04
US6143279A (en) 2000-11-07
US6022527A (en) 2000-02-08
ID29198A (id) 2001-08-09
EP1011688A1 (en) 2000-06-28
WO1999009998A1 (en) 1999-03-04
KR20010023359A (ko) 2001-03-26
AU9124998A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
ZA987847B (en) Method of treating lung diseases with uridine 5'-diphosphate and analogs thereof
PL331236A1 (en) Polynucleotidic vaccine composition against cattle's respiratory system diseases
IT9083334A0 (it) Procedimento per l'estrazione e la purificazione di dna genomico umano
PL320634A1 (en) Method of purifying and isolating 2'-deoxy - 2', 2' - difluoronucceosides
PL335301A1 (en) Derivatives of erythromycin 3"-n-dimethylamine-9-oxime 3'-n-oxide and method of obtaining them
PL312352A1 (en) 2,8-disubstituted quinazolinones, method of obtaining them and therapeutic agents containing such compounds
PL321046A1 (en) Method of obtaining 1-2'-deoxy-2',2'-difluoro-d-ribofuranosil)-4-amidopyrimidin-2-one hydrochloride
EP0772448A4 (en) CYCLIC ANALOGS OF PTH AND PTHrP
IL115015A0 (en) Methods of inhibiting demyelinating and desmyelinating diseases
HUP9900774A2 (en) Water solutions of 2-chloro-2'-deoxyadenosine formulations
GB2325931B (en) 5'-Deoxy-cytidine compounds and their use as anti-tumor agents
AU4965797A (en) Process for producing nucleoside 5'-triphosphates and application of the same
TR199701051A3 (tr) 2' -Fluoro-5-metil- -l-arabino-furanosilüridin hazirlanma prosesi
ZA959517B (en) Leutherobin and analogs thereof
EP0776211A4 (en) TREATMENT OF HISTIOCYTOSIS WITH 2-HALO-2'-DEOXYADENOSINE
PL336579A1 (en) Treatment of diseases associated with cytokinins
DE69403588D1 (en) 4-ethoxy-5-fluor-2'-deoxyuridine
GB2218417B (en) Preparation of 2'-deoxy-5,6-dihydro-5-fluoro-6-hydroxy uridine and diaryl 2'- deoxy-5-fluorouridines
AU6168296A (en) Chloroquine analogs and methods of preventing and treating p lasmodial disease
EP0783510A4 (en) HUMAN PROTEINS 1 AND 2 OF POTASSICAL CHANNELS
GB2323357B (en) Derivatives of 7-deaza-2-deoxy-guanosine-5'-triphosphate, preparation and use thereof
GR3033729T3 (en) Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
IL86670A0 (en) Preparation of 3'-azido-3'-deoxythymidine and intermediates therefor
ZA952797B (en) Method of treating auto-immune diseases using type one interferons
EP0755262A4 (en) PNEUMOPATHY TREATMENT COMPOSITION